Brentuximab vedotin is highly active in relapsed HL and was recently approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III/IV HL. We evaluated brentuximab-AVD for nonbulky stage I/II HL in a multicenter phase 2 study. Patients received a lead-in cycle...
Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA-ALCL.doi:10.1002/ccr3.1382Alderuccio, Juan PabloDesai, AmritaYepes, Monica M.Chapman, Jennifer R.Vega, FranciscoLossos, Izidore S.Clinical Case Reports...
Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leukemia & lymphoma. 2012 Nov; 53(11):2283-2286. [PubMed: 22424602]Nina D. Wagner-Johnston, Nancy L. Bartlett, Amanda Cashen, Joseph R. Berger. (2012) Progressive multifocal ...
Brentuximab vedotin (BV) is an antibody鈥揹rug conjugate, which has demonstrated impressive efficacy and safety in both of these histologies.Areas covered: BV was approved for the treatment of relapsed and refractory HL and anaplastic large cell lymphoma in the USA in 2011 and the European Union...
Brentuximab vedotinAn of the article "Successful desensitization to brentuximab vedotin after anaphylaxis," by A. E. O'connell is presented.reactions weekly
Brentuximab vedotin (BV) which is an anti-CD30 antibody-drug conjugate is a promising drug with effects on relapsing or refractory ALCL. However, its effects may not be sufficient for the central nervous system disease. The authors herein reported an 11-year-old boy with ALCL that progresse...
Berkowitz, Maurice JFintel, WilliamChen, RobertBoccia, Ralph VSaleh, MansoorJosephson, NeilBloodForero-Torres A, Holkova B, Sharman JP, et al. Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim...
Brentuximab vedotinEditorial comment: Details of this case report have previously been published [see Reactions 1533 p101; 803112269]. In this abstract, it was reported that the neuropathy in the 30-year-old woman was documented only in the first three courses of brentuximab vedotin....
Background\nBrentuximab vedotin (BV) is an antibody-drug conjugate (ADC) composed of a CD30-directed monoclonal antibody, a protease-cleavable linker, and the microtubule-disrupting agent, monomethyl auristatin E (MMAE). Direct cytotoxicity, driven by MMAE, is at the heart of the multifaceted ...
The trial CheckMate-436, including relapsed/refractory PMBL patients treated with nivolumab (antibody that binds to immune checkpoint PD-1) and brentuximab vedotin ((BV) anti-CD30 antibody-drug conjugate) showed an overall response rate (ORR) of 73% and complete response rate (CRR) of 43% (...